Synthesis and Evaluation of Alendronate-Modified Gelatin Biopolymer as a Novel Osteotropic Nanocarrier for Gene Therapy

Mekhail, George M.; Kamel, Amany O.; Awad, Gehanne A.S.; Mortada, Nahed D.; Rodrigo, Rowena; Spagnuolo, Paul A.; Wettig, Shawn

doi:10.2217/nnm-2016-0151

Cited by 36 publications

(9 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 2 c shows that the zeta potential of all samples was negative at pH 7.4, owing to the presence of the negatively charged HA and Ce6 [ 50 , 51 ]. Especially, (ALN)@dHA-Ce6, (ALN/cRGD)@HDOC-Ce6 NP, and (ALN/cRGD)@dHA-Ce6 have a very reduced zeta potential value owing to the presence of rich phosphoryl groups of ALN [ 52 , 53 ].…”

Section: Resultsmentioning

confidence: 99%

Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis

et al. 2020

View full text Add to dashboard Cite

In this study, we report the hyaluronate dot (dHA) with multiligand targeting ability and a photosensitizing antitumor model drug for treating metastatic bone tumors. Here, the dHA was chemically conjugated with alendronate (ALN, as a specific ligand to bone), cyclic arginine-glycine-aspartic acid (cRGD, as a specific ligand to tumor integrin αvβ3), and photosensitizing chlorin e6 (Ce6, for photodynamic tumor therapy), denoted as (ALN/cRGD)@dHA-Ce6. These dots thus prepared (≈10 nm in diameter) enabled extensive cellular interactions such as hyaluronate (HA)-mediated CD44 receptor binding, ALN-mediated bone targeting, and cRGD-mediated tumor integrin αvβ3 binding, thus improving their tumor targeting efficiency, especially for metastasized MDA-MB-231 tumors. As a result, these dots improved the tumor targeting efficiency and tumor cell permeability in a metastatic in vivo tumor model. Indeed, we demonstrated that (ALN/cRGD)@dHA-Ce6 considerably increased photodynamic tumor ablation, the extent of which is superior to that of the tumor ablation of dot systems with single or double ligands. These results indicate that dHA with multiligand can provide an effective treatment strategy for metastatic bone tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, ALN can also be grafted on carboxyl group of PT via functional groups such as amide on ALN. [ 20 ] The grafting results in the merging of the N–H bond vibration of ALN into ALN–PT spectra. Besides, after loading ALN, the morphology of PT scaffold changes to a highly irregular porous structure with decreasing pore size and wall thickness.…”

Section: Resultsmentioning

confidence: 99%

“…ALN is one of the most popular nitrogen-containing bisphosphonates used for the treatment of several systemic metabolic bone diseases and in biomedical engineering. [20] 2 | EXPERIMENTAL SECTION…”

Section: Introductionmentioning

confidence: 99%

Novel gelatin–graphene oxide crosslinking induced by nonthermal atmospheric pressure plasma for alendronate delivery system

Nguyen

Bolouki

Manga

et al. 2020

Plasma Processes & Polymers

View full text Add to dashboard Cite

Nonthermal atmospheric pressure plasma processes, including an interaction between plasma and liquid phases, are employed to induce crosslinked gelatin-graphene oxide composite hydrogels. The properties of thin-film hydrogel-forming postplasma treatment are analyzed by infrared spectroscopy, rheology, scanning electron microscope, and in vitro studies. The plasma-treated hydrogel (PT) exhibits an excellent gel strength with storage modulus up to 341 kPa and thermal stability of gel-sol transition at 65°C, elongated degradation time, and favorable cell viability. The practical application of PT demonstrates an efficient encapsulation and sustainable release of alendronate for at least 21 days. The results show that using nonthermal plasmas can be regarded as an alternative physical method to fabricate composite hydrogels for promising applications in drug carriers and biomedicine.

show abstract

“…Targeting ligands can enhance accumulation of the carrier system in as pecific tissue or cell type,m inimise non-specific uptake,and facilitate internalisation. Small molecules,such as folate, [141,148,163,222,223] alendronate, [224] lactose, [189] mannose, [113,[225][226][227] and TLR7 agonist, [208] as well as peptides, [207,228,229] oligonucleotides, [187] and polymers [68,129,142,172,173,222] have been introduced to biopolymerbased nanovectors in order to improve targeting of specific receptors (Figure 9, right). In addition to the choice of ligand, Internalisation can occur through an umber of endocytic pathways:pinocytosis (clathrin-mediated endocytosis, caveolae-mediated endocytosis, clathrin/caveolin-independent endocytosis), phagocytosis, and macropinocytosis.…”

Section: Target-specific Cell Uptakementioning

confidence: 99%

Biopolymer‐based Carriers for DNA Vaccine Design

et al. 2021

View full text Add to dashboard Cite

She studied chemistry at the University of Zagreb, and completed her PhD at the University of Strathclyde,G lasgow,w orking on DNA detection by advanced spectroscopies, such as SERRS. After postdoc research on DNA nanostructuring and artificial enzyme design at the University of Dortmund,s he was agroup leader at Karlsruhe Institute of Technology before joining Cambridge. Her research focuses on nanostructured biomaterials for use in photocatalysis and targeted drug delivery.

show abstract

Synthesis and Evaluation of Alendronate-Modified Gelatin Biopolymer as a Novel Osteotropic Nanocarrier for Gene Therapy

Abstract: ALN-gelatin is a promising biopolymer for bone targeting of either small molecules or gene therapy applications.

Cited by 36 publications

References 87 publications

Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis

Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis

Novel gelatin–graphene oxide crosslinking induced by nonthermal atmospheric pressure plasma for alendronate delivery system

Biopolymer‐based Carriers for DNA Vaccine Design

Contact Info

Product

Resources

About